The global Proteomics market is anticipated to grow at a significant CAGR of 9.7% during the forecast period. Personalized medicine has entered mainstream clinical practice and is transforming the way many diseases are detected, classified, and treated. It has become a fundamental topic of research in the healthcare business. Oncology is one area where these gains are particularly noticeable. The number of tailored medications, therapies, and diagnostic devices has expanded dramatically from 21% in 2014 to 42% in 2018, according to the Personalized Medicine Coalition report (2018), and this trend is projected to continue in the coming years. Furthermore, during the previous five years, biopharmaceutical companies have nearly doubled their R&D investments in customized medicine, and this trend is projected to continue in the next five years.
Browse the full report description “Global Proteomics Market Size, Share & Trends Analysis by Product (Instrumentation Technology, Reagents, and Software and Services), and by Application (Clinical Diagnostics, Drug Discovery, and Other Applications) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/proteomics-market
Proteomic analysis is a strong and appealing method for determining the molecular profiles of various tissues, whether healthy or sick. Personalized proteomics, also known as proteome profiling, is the next great step in personalized medicine; it clarifies illness pathomechanisms. This research identifies several indicators for a given condition and aids in the identification of protein targets for licensed medications, enabling therapeutic repositioning. This will have a direct impact on clinical practices by impacting key management and care features. These biomarkers can also be investigated for their therapeutic potential and future validation, as well as their utility as repeatable, sensitive, and specific diagnostic indicators.
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace. For instance, Perkin Elmer introduced the SARS-COV-2 Antigen Elisa Test in 2020. The IP2 software from Integrated Proteomics Applications was purchased by Bruker Corp. in 2020.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corp., Danaher Corp., GE Healthcare, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Inc., and Waters Corp, among others.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global Proteomics Market Report Segment
By Product
oSpectroscopy
oChromatography
oElectrophoresis
oProtein Microarrays
oX-Ray Crystallography
oOther Instrumentation Technologies
By Application
Global Proteomics Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/proteomics-market